Copyright © Inderes 2011 - present. All rights reserved.
  • Uusimmat
  • Pörssi
    • Aamukatsaus
    • Osakevertailu
    • Pörssikalenteri
    • Osinkokalenteri
    • Analyysi
    • Artikkelit
    • Sisäpiirin kaupat
  • inderesTV
  • Mallisalkku
  • Foorumi
  • Premium
  • Femme
  • Opi
    • Sijoituskoulu
    • Q&A
    • Analyysikoulu
  • Meistä
    • Seurantayhtiöt
    • Tiimi
Pörssitiedote

Duearity AB has signed a distributor agreement - covering Belgium, the Netherlands and Luxembourg

Duearity
Lataa tiedote

Duearity AB has today entered into an agreement with a distributor in the Netherlands who operates in Belgium, the Netherlands and Luxembourg. The distributor has evaluated Tinearity G1 and analyzed the conditions for the product in the three markets. Duearity is expected to enter into more distribution agreements and agreements with clinics in Europe and the United States in 2023 and 2024.

The distributor, Mediplast Benelux B.V., has evaluated Tinearity G1's conditions in Belgium, the Netherlands and Luxembourg. Among other things, statements from experts in tinnitus have been obtained. The conclusion is that Tinearity G1 has very good market conditions in the three countries. Marketing and sales will start in October 2023.
 
The distributor intends to carry out a pilot study which will be used as a basis in the application for Tinearity G1 to be included in the countries' subsidy systems.
 
The agreement is the company's third distributor agreement and Duearity AB thus covers Great Britain, Portugal, Belgium, the Netherlands and Luxembourg. The population of the five countries amounts to approximately 107 million people. Duearity will enter into more agreements in Europe and the US during 2023 and 2024.

For more information, please contact


Fredrik Westman, CEO
+46 738 - 145 215
fredrik.westman@duearity.com 
www.duearity.com

About Duearity AB (publ)


Duearity is a medtech company that develops and produces solutions aiming to relieve tinnitus symptoms and make everyday life easier for those who suffer from tinnitus. The company will offer the products Tinearity and Tinearity-AI.

Tinearity G1 is CE marked, has 510(k) clearance and is sold in the EU and in the US.

Tinearity transmits white noise using non-invasive Bone Conduction Technology to the inner ear in order to relieve symptoms. Tinearity AI will use artificial intelligence to help people anticipate the symptoms and relieve their discomfort.

The company is listed on Nasdaq First North. The company's headquarters are located in Malmö, Sweden.
Certified Adviser is Svensk Kapitalmarknadsgranskning AB (SKMG), www.skmg.se.
www.duearity.com.

Attachments


Duearity AB has signed a distributor agreement - covering Belgium, the Netherlands and Luxembourg

Sosiaalinen media
  • Inderes Foorumi
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Yhteystiedot
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • Meistä
  • Tiimi
  • Avoimet työpaikat
  • Inderes sijoituskohteena
  • Palvelut pörssiyhtiöille
Sivusto
  • UKK
  • Käyttöehdot
  • Tietosuojaseloste
  • Vastuuvapauslauseke
Inderesin vastuuvapauslauseke löytyy täältä. Kunkin Inderesin aktiivisessa seurannassa olevan osakkeen tarkemmat tiedot löytyvät kunkin osakkeen omilta yhtiösivuilta Inderes-sivustolla. © Inderes Oyj. Kaikki oikeudet pidätetään.